United States
Include All CSL Behring Country Sites

CSL Behring Foundation Awards Grants Totaling More Than $534,000 to Benefit Bleeding Disorders Community

Cutting-edge research and community awareness projects funded during latest grant cycle

King of Prussia, PA — 24 November 2008

The CSL Behring Foundation for Research and Advancement of Patient Health has awarded more than $534,000 in funding for programs designed to benefit the bleeding disorders community. The grants will support a range of initiatives, including research projects and programs developed to educate and support patients.

The Foundation awards grants on two occasions each year. In this cycle, seven organizations received eight awards.

An independent Advisory Council, consisting of hematologists, patients and other members of the bleeding disorders community with the sole authority to award the grants, reviews all grant requests in the two areas of scientific exploration and patient care/support. The CSL Behring Foundation is a non-profit organization dedicated exclusively to charitable, scientific and educational purposes that advance the standard of care for persons affected by bleeding disorders such as hemophilia and von Willebrand Disease. Since its inception in 2001, the CSL Behring Foundation has awarded millions of dollars in grants to the bleeding disorders community.

"CSL Behring is committed to improving the quality of life for people with rare diseases and we are proud to offer our continued support to researchers and advocates who are dedicated to helping those who cope with these often debilitating disorders," said Garrett E. Bergman, M.D., executive director of the CSL Behring Foundation. "We strongly encourage all eligible organizations to submit grant requests for future consideration." Two research grants, for more than $275,000, were awarded to Rush University Medical Center in Chicago and a grant for more than $190,000 was given to the University of North Carolina at Chapel Hill. These grants will be used to fund projects striving to improve the quality of life for hemophiliacs.

A patient grant to Hemophilia of North Carolina will fund an educational retreat for women affected by a bleeding disorder, such as von Willebrand Disease, and their teenage daughters. The retreat will feature experts in the field of treatment, genetics, advocacy and resources.

Other CSL Behring Foundation grant recipients are:

  • Florida Hemophilia Association (FHA) (Palmetto Bay, Fla.)
  • Hemophilia Foundation of Illinois (HFI) (Chicago, Ill.)
  • Hemophilia Foundation of Minnesota/Dakotas (HFMD) (Mendota Heights, Minn.)
  • The University of Colorado Denver – Hemophilia and Thrombosis Center’s Region VIII and Region X Nursing Group (Aurora, Colo.)

About the CSL Behring Foundation
Founded in 2001 as an independent, non-profit corporation, the CSL Behring Foundation for Research and Advancement of Patient Health is the only corporate foundation dedicated exclusively to charitable, scientific and educational purposes designed to advance the standard of care for persons affected by bleeding disorders. The CSL Behring Foundation is governed by an Advisory Council, consisting of healthcare professionals and advocates who are renowned for their dedication to the bleeding disorders community. The Advisory Council has the sole authority to award all grants.

For more information on the Foundation, visit www.cslbehringfoundation.com.

About Hemophilia
Hemophilia is an inherited bleeding disorder characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. About 17,000 Americans have hemophilia. The disease is caused by deficient or defective blood coagulation proteins known as factor VIII or IX. The most common form of the disease is hemophilia A, or classic hemophilia, in which the clotting factor VIII is either deficient or defective. Hemophilia B is characterized by deficient or defective factor IX.

About von Willebrand Disease
Von Willebrand disease is caused by a deficiency or abnormality of the von Willebrand factor, a protein in the blood that is necessary for normal blood clotting. Men and women are equally likely to be affected by VWD. VWD is classified by types, ranging from Type I (the most common and mild) to Type III (the most severe).

Women with VWD are more likely to experience heavy, prolonged menstruation. Other common symptoms of VWD include frequent nosebleeds and easy bruising. Bleeding can be mild or serious and can occur as a result of injury, or without any obvious cause. More serious symptoms include bleeding into joints and internal organs. The VWD patient may require special care during dental procedures, surgery and childbirth.

Treatments for VWD may include desmopressin acetate to release von Willebrand factor the patient has stored in their cells; von Willebrand factor replacement therapies, and oral contraceptives to reduce menstrual bleeding and raise von Willebrand factor in the bloodstream. Antifibrinolytic therapies are also used successfully to treat menorrhagia.

About CSL Behring
CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about saving and improving the quality of patients' lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of rare diseases such as immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, ZLB Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.cslbehring.com

Sheila A. Burke, Director,
Communications & Public Relations
Worldwide Commercial Operations
CSL Behring

Greg Healy, Senior Manager, Communications & Public Relations
U.S. Commercial Operations
CSL Behring

CRP16-05-0001 05/2016
© 2017 CSL Behring